Issue Archive

In this issue of Blood, Wildhagen et al demonstrate that nonanticoagulant heparin effectively blocks histone-mediated cytotoxicity and improves survival in animal models of severe infection and inflammation.¹ 

In this issue of Blood, Ludwig and colleagues present the data of a phase 2 clinical trial showing that bendamustine, bortezomib, and dexamethasone (BBD) is a very active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.¹  More importantly, BBD overcomes the adverse prognosis in patients with high-risk cytogenetics.

In this issue of Blood, Huang and colleagues examine the role of BACH2, a transcription factor known to be expressed highly in germinal center B cells.^1,-3 

In this issue of Blood, Clifford et al broaden the horizons of chronic lymphocytic leukemia (CLL) genetics by adding SAMHD1 to the compendium of driver genes recurrently mutated in this tumor.^1,2 

In this issue of Blood, Hoellenriegel et al provide evidence that NOX-A12, an RNA oligonucleotide able to bind and neutralize CXCL12, effectively interferes with chronic lymphocytic leukemia (CLL) cell chemotaxis and stroma-mediated drug-resistance.¹ 

In this issue of Blood, Aguilar and colleagues¹  present the result of a timely and much-needed investigation aimed to unveil the hidden sites of maturation of Plasmodium falciparum transmission stages in human malaria infections.

In this issue of Blood, Kolyada and colleagues elegantly demonstrate the therapeutic utility of a novel, synthetically constructed molecule, the A1 dimer (A1-A1), in preventing anti-β2 glycoprotein I (anti-β2GPI) autoantibody-mediated thrombosis in 2 distinct murine antiphospholipid syndrome (APS) thrombosis models. Current therapies for thrombotic APS entail long-term anticoagulation, with the associated risk of bleeding complications. The findings presented by Kolyada et al raise the possibility of perhaps using this agent to treat thrombotic APS patients in the future, allowing for a reduction in bleeding risk.¹